0001144204-18-005239.txt : 20180201
0001144204-18-005239.hdr.sgml : 20180201
20180201184114
ACCESSION NUMBER: 0001144204-18-005239
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180130
FILED AS OF DATE: 20180201
DATE AS OF CHANGE: 20180201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oliviero James F III
CENTRAL INDEX KEY: 0001434718
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38128
FILM NUMBER: 18568144
MAIL ADDRESS:
STREET 1: C/O KERYX BIOPHARMACEUTICALS, INC.
STREET 2: 750 LEXINGTON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc.
CENTRAL INDEX KEY: 0001651407
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472568632
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: 212-554-4366
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
4
1
tv484690_form4.xml
FORM 4
X0306
4
2018-01-30
0
0001651407
Checkpoint Therapeutics, Inc.
CKPT
0001434718
Oliviero James F III
2 GANSEVOORT ST, 9TH FLOOR
NEW YORK
NY
10014
0
1
0
0
CEO and President
COMMON STOCK (RESTRICTED)
2018-01-30
4
A
0
325000
0.00
A
1650000
D
The shares of restricted stock vest as follows: one-half on January 30, 2020, one-fourth on January 30, 2021 and one-fourth on January 30, 2022.
Includes (a) 1,000,000 shares of restricted stock that were granted on October 13, 2015, as previously reported, and are scheduled to vest as follows: (i) 444,444 shares on October 13, 2019; (ii) 222,222 shares on the later of April 1, 2019 or the Company's achievement of market capitalization goals; and (iii) 333,334 shares on the Company's achievement of goals relating to corporate development transactions and/or FDA approval; (b) 325,000 shares of restricted stock that were granted on December 15, 2016, as previously reported, and are scheduled to vest as follows: (i) 243,750 shares on December 15, 2019; and (ii) 81,250 shares on December 15, 2020; and (c) the 325,000 shares of restricted stock that were granted on January 30, 2018, as reported herein.
/s/ James F. Oliviero, III
2018-02-01